Search results
Author(s):
Julian Gillmore
Added:
1 year ago
AHA 2022 — Dr Julian Gillmore (University College London, London, UK) joins us to share the key findings from the CRISPR trial (NCT04601051).
This phase 1 study was conducted to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt…
View more
AHA 22 Late-Breaking Science Coverage
Video Series
Author(s):
Shu Nakao
,
Dai Ihara
,
Koji Hasegawa
,
et al
Added:
3 years ago
Induced Pluripotent Stem Cells and Their Potential Applications
Induced pluripotent stem cells (iPSCs) are generated from somatic cells, such as skin fibroblasts, by ectopic expression of defined reprogramming factors. Within a few years of the first report of the generation of mouse iPSCs, several laboratories reportedly reproduced these cells using other cell types and species using similar…
View more
Author(s):
Joseph A Hill
Added:
1 year ago
AHA 2022 — In this succinct video summary, Dr Joseph A Hill (University of Texas Southwestern Medical Center, Dallas, TX, US) Editor-in-Chief of Circulation shares his perspective on the highlights of AHA Scientific Sessions 2022.
What are the most impactful studies of AHA22?
00:00:43: CRISPR
01:41:08: IRONMAN
02:05:00: OCEAN(a)-DOSE
02:46:10: EMPA-KIDNEY
03:55:08: ISCHEMIA-EXTENDed
Access our…
View more
Author(s):
Rishi Rikhi
,
Michael D Shapiro
Added:
9 months ago
Author(s):
Cheng Keat Tan
,
David Bin-Chia Wu
,
Seh Yi Joseph Tan
,
et al
Added:
4 months ago
Added:
5 months ago
Source:
AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals.
Among the event’s highlights are eight late-breaking trial sessions, as listed below.
Watch our coverage of…
View more
Author(s):
Robert Voswinckel
,
Ralph T Schermuly
,
Norbert Weissmann
,
et al
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease defined by increasing pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to right heart failure. The life expectancy of patients with PAH who do not receive appropriate treatment is dramatically reduced. Guidelines for the diagnosis and treatment of PAH have been established by the American…
View more
Author(s):
Josef Kautzner
,
Petr Peichl
,
Rune Paamand
,
et al
Added:
4 months ago
Author(s):
Masafumi Funamoto
,
Yoichi Sunagawa
,
Yasufumi Katanasaka
,
et al
Added:
3 years ago
Topic: 3. Heart Failure and Cardiomyopathy
Introduction and Objectives
An intrinsic histone acetyltransferase (HAT), p300, is required for acetylation and the transcriptional activity of GATA4, as well as for pathological left ventricular hypertrophy (LVH) and the development of heart failure (HF) in vivo. Many studies of histone modification have been performed within the flexible tails of…
View more